In Vivo Models for Complex Surgical & Gene-Edited Studies | HuaTeng Biotech

Created on 10.23

In Vivo Models for Complex Surgical & Gene-Edited Studies | HuaTeng Biotech

What Are In Vivo Models for Preclinical Research?

In vivo models are experimental systems in which a biological question, a candidate drug, or a novel medical device is tested inside a living organism rather than in a culture dish or a computational simulation. Because they preserve intact physiology, in vivo models capture the constant interplay between the immune system, the vasculature, the nervous system, coagulation, and the local mechanical environment that in vitro assays simply cannot reproduce. They form the bridge between bench-level discovery and first-in-human trials, and regulators in the United States, Europe, and China expect sponsors to scientifically justify every model they rely on. Choosing the right species and the right induced condition is therefore not a procurement decision but a scientific one, because a poorly matched model produces data that looks precise yet predicts almost nothing about human outcomes. For complex surgical devices, orthopedic implants, vascular stents, wound dressings, and gene-edited disease lines, the difference between a small rodent and a purpose-bred large animal is frequently the difference between a shaky submission and a confident regulatory package. This is exactly the space in which HuaTeng Biotech operates, delivering customized large animal in vivo models that mirror real clinical scenarios rather than idealized laboratory conditions.
Species and model selection matter because anatomy, healing biology, and biomechanics diverge sharply across the animal kingdom, and those differences propagate directly into the endpoints a sponsor can measure. A pig coronary artery responds to stent implantation in ways that a rat aorta never will, a sheep long bone models human fracture healing far better than a mouse femur, and a rabbit ear or rabbit femoral artery offers a practical middle ground for early feasibility work. Investigators must also weigh practical variables such as animal size relative to the device, the availability of imaging modalities, the number of serial timepoints possible in one subject, and the ethical expectation that the least sentient species capable of answering the question should be used. Model selection guidance therefore begins with a clear statement of the clinical question, the intended regulatory pathway, and the endpoints that will ultimately decide success. HuaTeng Biotech structures every engagement around that logic, matching species, induced pathology, and follow-up schedule to the actual decision the sponsor needs to make.

Executive Summary: HuaTeng Biotech as a Specialized In Vivo Model Partner

HuaTeng Biotech is a preclinical research organization built specifically around in vivo models for complex surgical, interventional, orthopedic, vascular, wound, and peripheral artery disease research. Rather than acting as a general-purpose animal facility, the company concentrates on the technically demanding procedures that most contract laboratories decline: catheter-based interventions, device implantation under imaging guidance, critical-size bone defects, vascular anastomoses, and chronic ischemic wound models. Its platform spans multiple species including pigs, dogs, sheep, and rabbits, with dedicated capability for gene-edited large animal model generation using CRISPR and transgenic approaches. Sponsors range from medical device startups preparing a first regulatory submission to pharmaceutical and biologics groups that need pharmacodynamic or safety data in a physiologically relevant system. Every project is supported by in-house surgical and veterinary teams, imaging and physiological monitoring equipment, quality-controlled animal facilities, and a reporting pipeline that converts raw observations into submission-ready data. The result is a one-stop service that runs from model creation through endpoint analysis, described in more detail on theCRO Services page.

Why Translational Research Needs Large Animal In Vivo Models

The translational gap between in vitro work and small-animal studies is one of the most expensive problems in biomedical development, and it is well documented that a large share of compounds and devices that succeed in rodents later fail in humans. Cell culture cannot model flow-induced shear stress on an endothelial layer, the foreign-body response to an implanted polymer, or the mechanical loading that determines whether a bone graft consolidates. Rodent models, while indispensable for mechanistic work and early screening, differ from humans in scale, bone remodeling rate, coagulation cascade behavior, joint loading, and the healing kinetics of skin and soft tissue. Large animal in vivo models close much of that distance because pigs, dogs, sheep, and rabbits offer organ sizes, vessel calibers, and biomechanical environments close enough to a human patient that a surgeon can perform essentially the same operation. This clinical relevance is why regulators accept large animal data as pivotal support for device safety and why sponsors increasingly insist on it before committing to a costly clinical trial.
Pig models are favored for cardiovascular, wound, and abdominal surgery work because porcine coronary and peripheral arteries closely resemble human vessels in caliber and response to injury, and porcine skin shares structural features with human skin, including a similar dermal-epidermal thickness ratio. Dog models bring long, accessible peripheral vessels and a long history of validated interventional technique, which makes them useful for catheter-based device testing and vascular graft evaluation. Sheep models dominate orthopedic research because sheep bone density, cortical thickness, and remodeling behavior align well with human trabecular bone, and sheep are large enough to carry clinically sized implants under realistic load. Rabbit models provide a practical, ethically efficient intermediate step for orthopedic, vascular, and wound studies where a smaller but still non-rodent system is appropriate. HuaTeng Biotech maintains all four species platforms and advises sponsors on which combination best supports a phased program, an approach documented underAnimal Models.

Why Choose HuaTeng Biotech for In Vivo Model Studies

Sponsors choose HuaTeng Biotech because the company combines surgical depth with preclinical research discipline, a pairing that is genuinely rare in the contract research market. Custom protocol design starts with a feasibility conversation in which the team evaluates whether a proposed model can actually deliver the endpoint the sponsor needs, and suggests alternatives when it cannot. Experienced surgical and veterinary teams perform every procedure, from routine implant placement to complex reconstructive and catheter-based interventions, supported by anesthesia protocols tailored to each species and procedure. Imaging and physiological monitoring support includes fluoroscopy, ultrasound, and other modalities that allow device placement to be verified in real time and followed across serial timepoints in the same animal. Quality-controlled facilities, ethical and regulatory compliance programs, and scalable study execution mean a program can move from a pilot of a handful of animals to a multi-cohort pivotal study without changing partners. Detailed data reporting and one-stop service from model creation to endpoint analysis ensure that sponsors receive interpretable results rather than raw observations.
The practical advantage is continuity. When model creation, surgical execution, perioperative care, imaging, necropsy, histology, and reporting all sit inside one organization, fewer handoffs exist for information to degrade. That continuity also shortens the cycle time on protocol amendments, because the people who designed the model are the same people performing it and analyzing the outcome. HuaTeng Biotech also invests in reproducibility, standardizing surgical technique, anesthesia, analgesia, and endpoint timing so that results from different cohorts remain comparable. Sponsors who need to align a study with FDA, CE, or NMPA expectations can request GLP-compliant workflows and documentation, with supporting detail available on theMedical Device Testing In Vivo page. For programs spanning both drug and device evaluation, an integrated plan can be assembled through Preclinical Drug Development Solutions.

Model Portfolio by Species: Pigs, Dogs, Sheep, and Rabbits

The heart of the HuaTeng Biotech offering is a multi-species in vivo model portfolio that can be configured around a sponsor's clinical target rather than around whatever the facility happens to have available. Each species platform carries its own validated procedures, anesthesia protocols, and endpoint assays, and sponsors can combine platforms across a development program. Customization and species-selection guidance are provided at no additional cost during the scoping phase, because choosing the wrong species is far more expensive than discussing it up front.

Pig Models for Cardiovascular, Orthopedic, Wound, PAD, and Complex Surgical Research

Pig models underpin most of the cardiovascular, orthopedic, wound, and peripheral artery disease work performed at HuaTeng Biotech. Porcine coronary, femoral, and carotid arteries accept clinically sized stents, balloons, and grafts, allowing device performance to be assessed in a vessel with realistic compliance and flow. Porcine skin supports full-thickness wound, burn, and diabetic ulcer models with healing kinetics that translate credibly to human dermatology and wound care. Orthopedic pig models cover large bone defects, osteotomy, and joint procedures where implant size matches the human equivalent. Complex surgical pig models reproduce abdominal, thoracic, and reconstructive procedures at human scale, which makes them ideal for surgical training and for validating instruments intended for open or laparoscopic use. Because pigs tolerate serial anesthesia and imaging, sponsors can collect longitudinal data from a single cohort instead of sacrificing separate groups at each timepoint.

Dog Models for Interventional, Vascular, and Orthopedic Studies

Dog models remain a workhorse for interventional and vascular research thanks to their accessible peripheral anatomy and the extensive published literature that supports historical comparison. Catheter-based procedures such as angioplasty, stent deployment, embolization, and thrombectomy can be executed in canine vessels with a level of control that supports device safety claims. Canine orthopedic models support fracture fixation, joint replacement feasibility, and implant wear assessment in a species with well-characterized bone healing. The breadth of validated canine data means sponsors can often reference precedent in regulatory submissions rather than generating everything from scratch. HuaTeng Biotech's veterinary team manages perioperative care, analgesia, and rehabilitation monitoring throughout the study to protect both animal welfare and data quality.

Sheep Models for Orthopedic, Cardiovascular, and Wound Research

Sheep models are the reference standard for orthopedic in vivo research because ovine bone architecture and remodeling closely parallel human cancellous and cortical bone, and because sheep can bear weight on clinically sized implants. Critical-size segmental defects, fracture healing studies, spinal fusion, and cartilage repair work are all routinely performed in sheep at HuaTeng Biotech using standardized surgical approaches and validated radiographic scoring. Cardiovascular sheep models support valve, graft, and patch evaluation in a growing animal or adult animal depending on the question. Sheep wound models are useful for large-area dermal regeneration and biomaterial studies where a substantial surface area is needed to test a product as it would be used clinically. Because sheep are docile and tolerate long follow-up, they are well suited to studies that require months of implant integration data.

Rabbit Models for Orthopedic, Vascular, Wound, and Other Translational Studies

Rabbit models provide an efficient non-rodent step for orthopedic, vascular, wound, and general translational research. The rabbit femoral condyle, radius, and ulna are established sites for bone defect and fracture healing studies, while the rabbit ear and femoral artery support vascular graft and stenosis work at a manageable scale. Rabbit skin models are widely used for wound healing and dermal irritation assessment, and the species is large enough for surgical technique to remain clinically meaningful. HuaTeng Biotech uses rabbit models frequently as a screening bridge between rodent proof-of-concept and costly large animal work, which lets sponsors de-risk a device or biomaterial before committing to a full porcine or ovine study. Species-selection guidance helps sponsors decide when that intermediate step is worth the investment and when it is redundant.

Complex Surgical and Interventional Models

Complex surgical models are where the technical ceiling of a preclinical partner becomes visible, and they are a defining strength at HuaTeng Biotech. Surgical model creation covers open procedures such as graft implantation, anastomosis, organ resection, reconstructive repair, and orthopedic fixation, all performed under aseptic conditions with species-appropriate anesthesia and multimodal analgesia. Minimally invasive and catheter-based procedures allow devices to be delivered through the same access routes used in patients, which preserves the relevance of deliverability, trackability, and lesion creation data. Device testing integrates functional performance assessment with biocompatibility and safety endpoints so that a single study answers several questions at once. Imaging-guided interventions using fluoroscopy and ultrasound let surgeons position a device precisely and document placement before, during, and after the procedure. Preclinical safety and efficacy evaluation then converts those observations into a structured dataset covering device behavior, tissue response, and clinical pathology.
The value of performing complex surgical work in a large animal is that failure modes become visible early. A catheter that kinks in a bench model may perform perfectly in a porcine artery, or it may reveal a deliverability problem that no benchtop test could expose. A graft that appears acceptable histologically may show inadequate healing under real mechanical load. Because HuaTeng Biotech runs these procedures routinely, the team can anticipate complications, adjust technique without compromising study validity, and record the kind of procedural detail that regulators and reviewers ask about. Sponsors also gain access to surgical simulation and training services, which use the same models to prepare clinical investigators before first-in-human use.

Orthopedic, Vascular, Wound Healing, and PAD Models

Orthopedic models at HuaTeng Biotech span bone defect, fracture, joint, and cartilage applications, with each model designed around measurable radiographic, biomechanical, and histological endpoints. Critical-size segmental defects test whether a scaffold, graft, or biologic actually bridges a gap that would not heal spontaneously. Fracture models assess fixation stability, callus formation, and remodeling under controlled loading. Joint models address cartilage repair, meniscal substitution, and wear of implant materials, while spinal fusion models evaluate graft materials and osteoinductive factors. Endpoints combine micro-computed tomography, mechanical testing, and blinded histology so that structural and biological performance can be interpreted together.
Vascular models include graft implantation, stenosis induction, thrombosis assessment, and endothelial injury, each of which interrogates a different failure mode that matters clinically. Vascular graft studies evaluate patency, neointimal hyperplasia, and endothelialization over weeks to months. Stenosis and restenosis models test whether a device or drug reduces lumen loss after controlled injury, and thrombosis models assess thrombogenicity and the performance of antithrombotic coatings. Endothelial injury models are particularly useful for understanding how a device interacts with the vessel wall at the cellular level before human exposure. All vascular work is supported by angiography, intravascular imaging where appropriate, and detailed histopathology of the explanted segment.
Wound healing models cover acute and chronic wounds, including diabetic wound models that reproduce the impaired perfusion and delayed closure seen in patients with metabolic disease. PAD models create controlled hindlimb or peripheral ischemia to test revascularization strategies, angiogenic biologics, and cell therapies in a physiologically demanding environment. Functional endpoints such as perfusion imaging, limb function scoring, and tissue oxygenation are paired with histological assessment of capillary density, muscle regeneration, and fibrosis. Because wound and ischemia studies are sensitive to small differences in technique and animal condition, HuaTeng Biotech standardizes the procedural variables that most often confound results. This attention to detail is what makes wound healing models and PAD models from a single provider directly comparable across study phases.

Gene-Edited Large Animal Customization

Gene-edited large animal models extend the platform beyond induced disease into genetically defined disease, and HuaTeng Biotech supports this work with CRISPR-based editing and transgenic approaches. Knockout models remove a gene of interest to study loss of function in a physiologically relevant background, while knock-in and transgenic models introduce humanized sequences, reporter constructs, or disease-causing variants. Customization is available across pigs, dogs, sheep, and rabbits, with the species chosen according to the organ system, body size, and breeding timeline the project requires. Gene-edited pigs are particularly valuable for cardiovascular, metabolic, and xenotransplantation research, while gene-edited sheep and rabbits serve orthopedic, ophthalmic, and rare disease programs. Breeding, phenotyping, and validation are handled in-house so that sponsors receive characterized animals with confirmed genotypes and documented phenotypes rather than unverified founders.
The applications of gene-edited large animal models are expanding quickly into rare disease research, regenerative medicine, and device testing. A genetically defined large animal can serve as a longitudinal disease model in which a therapy is tested against a consistent, heritable pathology rather than a surgically induced approximation. In regenerative medicine, humanized or immunodeficient large animals help evaluate cell and tissue-engineered products in a setting closer to clinical use. In device testing, a disease-specific genetic background can reveal performance differences that a healthy animal would never expose. HuaTeng Biotech works with sponsors to define the editing strategy, breeding plan, phenotyping battery, and validation package up front, because gene-edited programs reward careful planning and punish late changes.

Study Workflow and Quality Assurance

Every engagement at HuaTeng Biotech follows a structured workflow that begins with consultation and feasibility assessment. During this stage the team reviews the scientific question, the intended regulatory use, the required endpoints, and any constraints on timeline or sample size, then recommends a species and model configuration. Protocol and ethics review follows, with documentation prepared for institutional animal care and use committee approval and, where required, GLP-aligned quality systems. Anesthesia and perioperative care are standardized by species and procedure, including pain scoring, analgesia plans, and daily welfare monitoring. Imaging and biomarker sampling occur at protocol-defined intervals so that longitudinal data are captured consistently rather than opportunistically. Pathology and histology, including gross necropsy, slide preparation, and blinded scoring, convert the final timepoint into interpretable evidence for the final report.
Quality assurance runs through the entire workflow rather than sitting at the end of it. HuaTeng Biotech emphasizes animal welfare as both an ethical obligation and a data-quality issue, because stressed or poorly managed animals generate noisy results that undermine reproducibility. Facility operations, environmental monitoring, and record keeping are controlled so that a study can be reconstructed and audited afterward. The final report packages methods, deviations, raw data, imaging, histology, and interpretation in a format sponsors can drop directly into an investigator brochure or a regulatory submission. Additional information on the underlying platforms, including imaging, molecular biology, and histopathology, is available on theResources page.

Applications and Proof Points

The applications for customized in vivo models cut across medical devices, pharmaceuticals, biologics, biomaterials, regenerative medicine, and surgical training. A device sponsor may need a porcine stent study with angiographic follow-up at 30 and 90 days, while a biologics group may need an ovine bone defect model to demonstrate osteoinductive activity. Biomaterial developers frequently require both a rabbit screening study and a sheep confirmatory study to satisfy reviewers. Regenerative medicine programs often combine a gene-edited large animal with a surgical defect model to test a cell-based therapy in a disease-relevant background. Surgical training programs use the same models to prepare clinical teams, which is an efficient secondary use of an established platform.
The table below summarizes how species and model types are typically matched, based on the patterns HuaTeng Biotech sees across its project portfolio. It is a starting point for discussion rather than a rule, because the clinical question always determines the final configuration.
Species
Primary Model Types
Typical Applications
Pig
Cardiovascular, orthopedic, wound, PAD, complex surgical
Stents, grafts, implants, diabetic wounds, ischemia, laparoscopic training
Dog
Interventional, vascular, orthopedic
Catheter devices, thrombectomy, vascular grafts, fracture fixation
Sheep
Orthopedic, cardiovascular, wound
Critical-size bone defects, spinal fusion, valves, dermal regeneration
Rabbit
Orthopedic, vascular, wound, translational screening
Bone healing, graft patency, dermal repair, early feasibility
Gene-edited (all species)
Knockout, knock-in, transgenic disease models
Rare disease, regenerative medicine, humanized models, device testing
Anonymized case examples illustrate the range. In one program, a sponsor developing a bioresorbable vascular scaffold required serial angiography in a porcine coronary model with histology at 180 days; the resulting dataset supported a submission package without a repeat study. In another, a bone graft substitute was first screened in a rabbit femoral condyle defect and then confirmed in an ovine segmental defect, which saved the sponsor from advancing a formulation that could not bridge a load-bearing gap. A third program required a gene-edited pig line with a specific metabolic phenotype for a long-term device evaluation, and the breeding and phenotyping plan was built alongside the surgical protocol so that animals reached the study at the correct age and health status.

Discussion: Reducing Translational Risk with a Multi-Species Platform

HuaTeng Biotech's multi-species platform and complex surgical expertise reduce translational risk in a way that a single-species laboratory cannot. Sponsors can stage a program deliberately, using a rabbit or canine model to answer a narrow feasibility question and reserving porcine or ovine work for the confirmatory study that regulators will scrutinize. That staging keeps costs proportionate while preserving the option to escalate to a more clinically relevant system if early data are promising. Because the same organization executes each stage, technique, reporting standards, and endpoint definitions remain consistent across the program, which makes cross-species comparison far more defensible. The gene-edited capability adds a further dimension, allowing a sponsor to move from an induced pathology to a heritable disease model without leaving the platform.
Limitations deserve honest treatment. Large animal studies are more expensive, slower, and more heavily regulated than rodent work, and they should never be initiated before the underlying biology is sufficiently understood. Each species carries its own anatomical and physiological peculiarities, and no animal model perfectly reproduces human disease, so sponsors must decide which similarities matter for their specific claim and which differences are tolerable. Sample sizes are constrained by ethics and cost, which raises the importance of careful endpoint selection and statistical planning. There is also a genuine trade-off between model complexity and reproducibility: a more elaborate surgical model may be more clinically relevant but harder to standardize across cohorts. HuaTeng Biotech addresses these trade-offs through feasibility assessment and protocol design rather than by promising a perfect model, and the company's track record and certifications are summarized on theAbout Us page.

Conclusion: Customized In Vivo Models from HuaTeng Biotech

HuaTeng Biotech provides customized in vivo models for sponsors who need preclinical data that genuinely predict clinical performance. The combination of multi-species coverage, complex surgical and interventional capability, orthopedic, vascular, wound, and PAD expertise, and gene-edited large animal customization covers most of the technically difficult questions in translational research. A single partner handles protocol design, ethics review, surgery, perioperative care, imaging, histology, and reporting, which reduces handoffs and protects data integrity. Sponsors gain a team that has performed these procedures many times and can therefore anticipate problems before they consume a cohort. For programs moving toward FDA, CE, or NMPA submission, the resulting documentation is structured for review rather than retrofitted afterward. To discuss a protocol, request a feasibility assessment, or obtain a quote, visit theContact Us page or start from the HOME page to explore the full service portfolio.

Frequently Asked Questions (FAQ)

Which species should I choose for my in vivo models?

The right species depends on the clinical question, the device size, and the endpoints you intend to measure. Pigs suit cardiovascular, wound, PAD, and complex surgical work because vessel caliber and skin structure resemble human anatomy, while sheep are preferred for orthopedic studies involving load-bearing implants. Dogs offer accessible peripheral vessels for interventional and vascular work, and rabbits provide an efficient non-rodent step for early feasibility. HuaTeng Biotech provides species-selection guidance during the scoping phase so the model matches the regulatory claim rather than convenience.

Can you customize gene-edited large animal models for my program?

Yes. HuaTeng Biotech supports CRISPR-based knockout and knock-in approaches as well as transgenic model generation in pigs, dogs, sheep, and rabbits. Customization covers editing strategy, breeding plans, phenotyping batteries, and genotype and phenotype validation. Gene-edited programs benefit from early planning, so sponsors are encouraged to discuss the target gene, the desired phenotype, and the timeline before committing to a breeding scheme.

What ethical and regulatory standards apply to in vivo models?

All studies follow institutional animal care and use committee review, with protocols written to address the three Rs of replacement, reduction, and refinement. HuaTeng Biotech operates quality-controlled facilities with standardized anesthesia, analgesia, and welfare monitoring, and can execute GLP-compliant workflows for programs intended to support FDA, CE, or NMPA submissions. Documentation is maintained so that studies can be audited and reconstructed after the fact.

What timelines and deliverables should I expect from a large animal study?

Timelines depend on species, model complexity, and follow-up duration, ranging from a few weeks for an acute device study to many months for orthopedic or gene-edited programs. Deliverables typically include the approved protocol, surgical and perioperative records, imaging data, clinical pathology, gross necropsy findings, histology slides and scoring, raw datasets, and a final integrated report. HuaTeng Biotech defines the deliverable list during contracting so there are no surprises at closeout.

Do you support complex surgical models and catheter-based interventional models?

Yes, this is a core specialization. The team performs open surgical model creation, minimally invasive procedures, catheter-based device delivery, and imaging-guided interventions using fluoroscopy and ultrasound. These capabilities support device testing, preclinical safety and efficacy evaluation, and surgical simulation and training for clinical teams preparing for first-in-human use.

How are orthopedic, vascular, wound healing, and PAD models evaluated?

Evaluation combines functional and histological endpoints chosen for the specific claim. Orthopedic work uses imaging such as micro-computed tomography, mechanical testing, and blinded histology, while vascular studies assess patency, neointimal hyperplasia, thrombosis, and endothelialization. Wound healing models track closure kinetics, perfusion, and tissue architecture, and PAD models combine perfusion imaging and limb function scoring with capillary density and muscle histology.

What is the advantage of large animal in vivo models over rodent studies?

Large animal in vivo models reproduce human-scale anatomy, biomechanics, and healing biology more faithfully than rodents, which matters for device deliverability, implant loading, and wound closure. They allow clinically sized devices to be tested through the same access routes used in patients and support serial sampling in the same subject. That relevance is why regulators accept large animal data as pivotal support for many device submissions.

Can in vivo models be used for both drug and medical device development?

Yes. The same species platforms support pharmacodynamic evaluation, pharmacokinetic sampling, biologics testing, biomaterial assessment, and device safety and performance studies. HuaTeng Biotech builds integrated programs where a single species and surgical model serves multiple questions, which reduces total animal use and keeps data internally consistent across a development plan.

Which applications benefit most from customized in vivo models?

Medical devices, orthopedic implants, vascular grafts, wound care products, biomaterials, regenerative medicine therapies, and gene-edited disease models all benefit strongly. Surgical training and procedure development are another common application, since the models allow clinical teams to rehearse technique before patient exposure. Customization ensures the model reflects the exact indication rather than a generic approximation.

How do I start a project or request a quote?

Begin with a consultation describing your clinical question, target species preferences, required endpoints, and timeline. HuaTeng Biotech will conduct a feasibility assessment, recommend a model configuration, and provide a scope and quote covering model creation through endpoint analysis. Sponsors can submit an inquiry through the contact form to schedule that initial discussion.
Contact
Leave your information and we will contact you.

Copyright ©️ 2022, NetEase Zhuyou(and its affiliates as applicable). All Rights Reserved.

Company

Collections

About

Follow us

Team&Conditions

Work With Us

Featured Products

News

LinkedIn

All products

Shop

Facebook

Twitter

phone
Email